Clinical trial · Interventional
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
A Phase I Single Arm,Open-label,Multiple Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
NCT04865458CI-TRIAL-00111621terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Adjustment to the sponsor's development strategy
Summary
Brief summary (as posted)
Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory B-cell Hematologic Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HEC89736 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HEC89736 treatment
- description
- HEC89736 tablets,25 mg, 50 mg, 100 mg, 150 mg, 200 mg, QD, 28 days for each cycle
- interventionNames
- Drug: HEC89736
Primary outcomes (2)
- measure
- Dose limited toxicities evaluated with NCI-CTC AE v5.0 after the first dose
- timeFrame
- Dosing started until the 28th day
- description
- Incidence of dose limited toxicities and associated dose of HEC89736
- measure
- Adverse events evaluated by NCI CTCAE 5.0
- timeFrame
- From the frst dose to within 30 days after the last dose
- description
- Incidence of adverse events and associated dose of HEC89736
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age is over 18 years old * Histologically or cytologically diagnosed patients with recurrent or refractory B-cell malignancies * ECOG performance status (PS) 0 \~ 1 * Expected survival of \> or = 3 months Exclusion Criteria: * The use of PI3Ks as the target of anti-tumor drugs progress (due to intolerance group) * Received any other anti-cancer treatment within 4 weeks * Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors that affect drug use and absorption * Allergy, or known to have a history of allergy to the drug components
References
Publications (0)
Data not yet available
No reference posted for this study.